NCI-2024-07313

A multicentre, Phase II, single-arm, interventional study of neoadjuvant durvalumab and platinum-based chemotherapy(CT), followed by either surgery and adjuvant durvalumab or chemoradiotherapy (CRT) and consolidation durvalumab, in participants with resectable or borderline resectable stage IIB-IIIB Non-small Cell Lung Cancer (NSCLC)

This is a Phase II study taking place at multiple hospitals to test a treatment for people with stage IIB-IIIB Non-Small Cell Lung Cancer (NSCLC) that can either be removed by surgery or is close to being able to be removed. First, patients will receive a combination of durvalumab, a drug that helps the immune system fight cancer, and platinum-based chemotherapy, which uses special drugs to kill cancer cells. After this, patients will either have surgery and then more durvalumab (called adjuvant durvalumab) or receive chemoradiotherapy (CRT), which combines chemotherapy and radiation, followed by more durvalumab (called consolidation durvalumab). The goal is to see how well this combination works in treating this type of lung cancer.

Phase 2: An advanced point of testing, where they're trying to confirm if a treatment works well.

non-small cell lung cancer (NSCLC): A type of lung cancer with non small cells that grow too much and can spread to other parts of the body

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT05925530

Clinical Trial Site: Einstein

To see all available clinical trials click here.